New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease

Abstract

Patients with inflammatory bowel disease (IBD) are at a high risk of developing invasive pneumococcal infection both before and after they are diagnosed. The Advisory Committee on Immunization Practices now endorses use of 2 new pneumococcal conjugate vaccines, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20), for patients who have never received a pneumococcal conjugate vaccine or those with unknown vaccination history. Previous studies have shown that pneumococcal vaccination can decrease the risk of developing severe pneumococcal disease; therefore, it is important that patients with IBD receive pneumococcal vaccination. This report aims to inform clinicians who care for patients with IBD about the changes in immunization practices, as it pertains to pneumococcal vaccination and provides appropriate direction on administering vaccination series.

Interactions and Implications of Klebsiella pneumoniae with Human Immune Responses and Metabolic Pathways: A Comprehensive Review

“…The recent adoption by the US Food and Drug Administration (FDA) of new pneumococcal conjugate vaccines (PCVs), namely PCV15 (Vaxneuvance) and PCV20 (Prevnar 20), 66 targeting Streptococcus pneumoniae , may offer valuable insights for potential application against K. pneumoniae in the future. Current research is exploring factors involved in biofilm formation as potential vaccine candidates against K. pneumoniae , with a focus on the anti-biofilm properties of induced antibodies.…”

Rapid Adoption of Pneumococcal 20-Valent Conjugate Vaccination in Adult Patients With Inflammatory Bowel Disease: An Analysis One Year After Availability

“…In the study by Dasharathy and colleagues, the authors noted that provider recommendations for pneumococcal vaccination occurred in >50% of patients with IBD; however, only 40% received one pneumococcal vaccine (either PPSV23 or PCV13) and only 18% completed the 2-dose pneumococcal vaccination series (PPSV23 and PCV13). In light of the newly updated ACIP recommendations for the use of the single-dose PCV20, 3,4 we investigated our internal database to elucidate provider pneumococcal vaccination practice after the institutional availability of PCV20 in March 2022. In addition, to investigate vaccine uptake, we sought to compare monthly vaccination administration in the year after PCV20 availability to that of the year prior.…”